Latest California Healthline Stories
Eyes Fixed On California As Governor Ponders Inking Drug Price Transparency Bill
“If it gets signed by this governor, it’s going to send shock waves throughout the country,” one legislator says. Pharma has spent $16.8 million to lobbying against this bill and other drug laws in California.
Más pacientes del Medicaid y presos podrán tratarse con una droga contra la hepatitis C
El tratamiento con una droga aprobada por la Administración de Drogas y Alimentos cuesta menos y cura la hepatitis C en alrededor de dos meses. Pacientes vulnerables tendrían más acceso a esta terapia.
Hepatitis C Drug’s Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment
The drug, sold under the name Mavyret, can cure all six genetic types of the liver disease in eight weeks at a cost of $26,400, well below other options.
Right After Trump Blamed High Drug Prices On Campaign Cash, Drugmakers Gave More
At a political rally in March, President Donald Trump said drug prices are “outrageous” and blamed campaign contributions. Drugmakers funneled nearly $280,000 to Congress the very next day.
Everyone Says We Must Control Exorbitant Drug Prices. So, Why Don’t We?
Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.
High On Drugs? Anthem Cites Soaring Drug Costs To Justify 35% Rate Hike in California
The company’s drug spending prediction, far above other insurers in the individual market, has experts scratching their heads. Anthem cites market volatility.
State Lawmakers Tackle Public Smoking And Lead Poisoning, But Punt On Single-Payer
California lawmakers adopted a drug price transparency bill and several other key health care measures as their legislative session ended last week, but they pushed off decisions on some big-name proposals such as single-payer health care.
California Drug Price Bill Sweeping In Scope, Lacking In Muscle
The proposal, which is headed to the desk of Gov. Jerry Brown, would impose new reporting requirements on drugmakers and health plans but wouldn’t have the power to bring down prices directly.
FDA Guards Against Abuse Of ‘Orphan Drug’ Program
Following a KHN and NPR investigation, the Food and Drug Administration has moved to speed up approvals of “orphan drugs” while closing a loophole that allowed drugmakers to skip pediatric testing.
Facebook Live: The Prescription Drug Pricing Pipeline
In this Facebook Live, KHN’s Julie Appleby talks with Stephanie Stapleton and answers readers’ questions about the prescription drug pricing pipeline and the industry stakeholders who have a role in what you pay.